More people entered the labor force, and not all were able to find jobs right away. Bad weather may have been a factor
Consumers like curation—stories that narrow the choices down to the best two or three
With yet another tweak to the health-care law, the Obama administration is heading off a popular Republican attack
Music executives are tapping services such as Shazam and Spotify to help predict tomorrow’s next big hits
In the five years since the most recent bottom, the stock market has very nearly tripled
Arunachalam Muruganantham, aka "Menstrual Man," designed simple devices that allow rural Indian women to make their own sanitary pads
The company's dubbing of storms with Greek and Latin names began in 2012 to help 'personalize' extreme weather
European MBA programs compete with top-tier U.S. schools for the best students at home and abroad
Organizations offer special training for senior entrepreneurs
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."